中国偏头痛患病群体庞大,2021年约有1.85亿患者,相当于每10人中就有1人受此困扰 1。该疾病已被列为世界第二大致残性疾病 1。然而,国内具备规范诊疗能力的神经内科医生资源不足,导致诊断现状不容乐观 1。2026年一项覆盖国内28个省份、涉及超过1万名患者的研究显示,仅三成偏头痛患者曾获得正确诊断,即便是专科医生的正确诊断率也不到一半 1。
在长期疼痛折磨与正规医疗资源匮乏的双重压力下,部分患者转向缺乏临床证据支持的治疗手段或过度依赖止痛药物 1。以患者李明(化名)为例,他于2026年8月在北京接受了“经皮卵圆孔未闭封堵手术” 1。尽管该手术声称有90%的概率治愈偏头痛,但国内外主流医学界并不推荐将其作为常规治疗方案,因其尚缺乏足够的临床证据支撑 1。
目前,曲普坦类药物被视为偏头痛的特效药,其机制在于减轻颅内血管异常扩张并抑制神经肽释放,但此类药物无法根治疾病 1。相比之下,氨基比林咖啡因片(俗称脑清片)因可能引发粒细胞缺乏症等副作用,在现代头痛治疗中已鲜少使用 1。偏头痛患者的求医历程折射出基层医疗资源的短板以及非主流疗法盛行的现实困境 1。
China’s migraine patients are grappling with severe diagnostic and treatment challenges. According to 2021 data, approximately 185 million people in the country suffer from migraines, meaning one in every ten individuals is affected 1. The condition is also ranked as the second leading cause of disability worldwide 1. However, a 2026 study involving over 10,000 patients across 28 Chinese provinces revealed that only 30% had ever received a correct diagnosis, while even specialists achieved a correct diagnosis rate of less than 50% 1. These figures highlight a shortage of neurologists with relevant clinical expertise, leaving many patients without proper care 1.
Driven by long-term pain and limited access to effective medical services, some patients turn to unproven therapies or rely heavily on painkillers. In August 2026, a patient identified by the pseudonym Li Ming underwent a "percutaneous patent foramen ovale closure" procedure in Beijing at a cost of 30,000 yuan 1. The surgery was promoted with claims of a 90% cure rate for migraines, but mainstream medical communities both in China and internationally do not recommend it as a routine treatment due to insufficient clinical evidence 1. Another common scenario involves patients relying on pain medication for decades to manage symptoms 1. While aminopyrine caffeine tablets (commonly known as "Naoqing Pian") have largely fallen out of use in modern headache therapy due to the risk of agranulocytosis, triptans remain effective specific medications for migraines; they work by reducing abnormal dilation of intracranial blood vessels and inhibiting the release of neuropeptides, yet they cannot cure the disease 1. These trends collectively reflect the scarcity of primary healthcare resources and the prevalence of non-standard treatments 1.
评论
还没有评论,欢迎留下第一条。